Penn FTD Center's Co-Director Corey McMillan and University of Miami's Michael Benatar are starting a new NIH-funded study titled "C9orf72 ALS/FTD Prevent". 330 individuals with a C9orf72 expansion will be enrolled in this multi-center national study.
Want to learn more? Join the free webinar on Monday, November 9th at 6:00pm EST by scanning the QR code or using the link below.
University of Pennsylvania Frontotemporal
Degeneration Center
The University of Pennsylvania Frontotemporal Degeneration Center (Penn FTD Center) is an internationally recognized advanced clinical care and research facility for individuals with frontotemporal degeneration (FTD) and other early-onset dementias. The Penn FTD Center is dedicated to maintaining an active, engaged presence in the global effort to combat FTD, with compassion and innovation, for the benefit of all those affected.
Our Mission
Our mission is to improve the lives of individuals and families affected by frontotemporal degeneration (FTD) and related disorders. At the Penn FTD Center, we provide compassionate, team-based care while working to better understand FTD and develop more effective treatments. We are committed to supporting our community through education, promoting health equity, and offering resources and meaningful support every step of the way. We are committed to advancing science towards a cure, training future leaders in the field to bring hope for a world without FTD.
